Beam Therapeutics Inc.
Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence

Abstract:

The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.